Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PSNL NASDAQ:TEM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePSNLPersonalis$10.78-3.2%$6.95$3.84▼$11.85$1.13B2.281.82 million shs2.90 million shsTEMTempus AI$47.51-4.3%$48.81$41.73▼$104.32$8.53B3.645.75 million shs6.42 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePSNLPersonalis-1.07%+24.61%+92.73%+24.75%+130.64%TEMTempus AI-6.02%+6.34%-9.81%-3.26%-21.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePSNLPersonalis$10.78-3.2%$6.95$3.84▼$11.85$1.13B2.281.82 million shs2.90 million shsTEMTempus AI$47.51-4.3%$48.81$41.73▼$104.32$8.53B3.645.75 million shs6.42 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePSNLPersonalis-1.07%+24.61%+92.73%+24.75%+130.64%TEMTempus AI-6.02%+6.34%-9.81%-3.26%-21.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePSNLPersonalis 2.57Moderate Buy$11.002.04% UpsideTEMTempus AI 2.47Hold$68.6444.48% UpsideCurrent Analyst Ratings BreakdownLatest PSNL and TEM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026TEMTempus AI Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform6/1/2026TEMTempus AI BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.006/1/2026TEMTempus AI Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.005/12/2026PSNLPersonalis Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$10.00 ➝ $9.005/11/2026TEMTempus AI HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$95.00 ➝ $64.005/11/2026PSNLPersonalis BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $11.005/8/2026TEMTempus AI BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$90.00 ➝ $80.005/6/2026TEMTempus AI TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$65.00 ➝ $68.004/21/2026PSNLPersonalis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026TEMTempus AI TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$65.004/13/2026TEMTempus AI Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageUnderperform$35.00(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPSNLPersonalis$69.65M16.21N/AN/A$2.94 per share3.67TEMTempus AI$1.36B6.25N/AN/A$2.76 per share17.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePSNLPersonalis-$81.27M-$1.02N/AN/AN/A-148.11%-43.52%-32.92%8/4/2026 (Estimated)TEMTempus AI-$245.03M-$1.72N/AN/AN/A-22.20%-53.83%-11.17%8/14/2026 (Estimated)Latest PSNL and TEM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026PSNLPersonalis-$0.23-$0.29-$0.06-$0.29$14.49 million$15.47 million5/5/2026Q1 2026TEMTempus AI-$0.21-$0.13+$0.08-$0.71$345.44 million$348.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthPSNLPersonalisN/AN/AN/AN/AN/ATEMTempus AIN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPSNLPersonalisN/A6.616.44TEMTempus AI2.963.313.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPSNLPersonalis61.91%TEMTempus AI24.22%Insider OwnershipCompanyInsider OwnershipPSNLPersonalis4.20%TEMTempus AI24.26%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePSNLPersonalis400104.72 million100.32 millionOptionableTEMTempus AI3,800179.57 million136.00 millionN/APSNL and TEM HeadlinesRecent News About These CompaniesTempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding MembersJune 3 at 8:30 AM | businesswire.comTempus AI, Inc. (TEM) Analyst/Investor Day TranscriptJune 3 at 8:01 AM | seekingalpha.comAI News You Need to Know — June Edition: Capex, Inference, & BeyondJune 3 at 7:37 AM | etftrends.comEStifel Nicolaus Sticks to Its Hold Rating for Tempus AI, Inc. Class A (TEM)June 2 at 2:26 PM | theglobeandmail.comTempus AI (NASDAQ:TEM) Now Covered by Analysts at Wolfe ResearchJune 2 at 10:03 AM | marketbeat.comH.C. Wainwright Maintains Buy Rating on Tempus AI (TEM) Following Strong Revenue GrowthJune 2 at 7:30 AM | insidermonkey.comTempus AI, Inc. $TEM Shares Bought by Lingotto Investment Management LLPJune 2 at 6:55 AM | marketbeat.comAXQ Capital LP Buys Shares of 26,002 Tempus AI, Inc. $TEMJune 2 at 3:13 AM | marketbeat.comShort Report: Tempus AI short interest at record highJune 1 at 6:15 PM | finance.yahoo.comTempus AI (TEM) Is Up 9.3% After New FDA-Cleared CDx And AI Oncology Platform UpgradesJune 1 at 6:15 PM | finance.yahoo.comTempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xHJune 1 at 9:00 AM | businesswire.comTempus AI's (TEM) Buy Rating Reaffirmed at BTIG ResearchJune 1 at 8:12 AM | marketbeat.comTempus AI (NASDAQ:TEM) Receives "Buy" Rating from Needham & Company LLCJune 1 at 8:12 AM | marketbeat.comArtificial Intelligence Stocks To Research - May 31stJune 1 at 5:36 AM | americanbankingnews.comTempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug DevelopmentMay 31 at 8:30 AM | businesswire.comTempus AI, Inc. $TEM Shares Bought by Legal & General Group PlcMay 31 at 4:58 AM | marketbeat.comTempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive ResultsMay 31 at 4:26 AM | finance.yahoo.comTempus Introduces 'Preview': Bridging the Critical Time Gap Between Diagnostic Order and Definitive ResultsMay 30, 2026 | gurufocus.comTempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research CommunityMay 30, 2026 | businesswire.comTempus Introduces ‘Preview': Bridging the Critical Time Gap Between Diagnostic Order and Definitive ResultsMay 30, 2026 | businesswire.comTempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 166,250 SharesMay 30, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePSNL and TEM Company DescriptionsPersonalis NASDAQ:PSNL$10.78 -0.36 (-3.23%) Closing price 04:00 PM EasternExtended Trading$10.68 -0.10 (-0.94%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.Tempus AI NASDAQ:TEM$47.51 -2.11 (-4.25%) Closing price 04:00 PM EasternExtended Trading$46.73 -0.78 (-1.65%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coke's $10B India IPO Plan Pops the Top on Hidden Value Palo Alto Networks Accelerates Growth 31% on AI Demand Motorola's $1.5B Bet to Own the Skies Microsoft Build 2026 Is Really Just One Big AI Stress Test FedEx Unboxes Billions in Post-Spinoff Value Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter What IBM's $10-Billion Quantum Project Means For Smaller Players Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
